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Background: Plasmodium falciparum gametocytes, specifically mature stages, are the only stage in man
transmissible to the mosquito vector responsible for malaria transmission. Anti-malarial drugs capable of killing
these forms are considered essential for the eradication of malaria. The comprehensive profiling of in vitro activity
of anti-malarial compounds against both early (I-III) and late (IV-V) stage P. falciparum gametocytes, along with the
high throughput screening (HTS) outcomes from the MMV malaria box are described.
Method: Two anti-gametocyte HTS assays based on confocal fluorescence microscopy, utilizing both a gametocyte
specific protein (pfs16-Luc-GFP) and a viability marker (MitoTracker Red CM-H2XRos) (MTR), were used for the measurement
of anti-gametocytocidal activity. This combination provided a direct observation of gametocyte number per assay well,
whilst defining the viability of each gametocyte imaged.
Results: IC50 values were obtained for 36 current anti-malarial compounds for activities against asexual, early and late
stage gametocytes. The MMV malaria box was screened and actives progressed for IC50 evaluation. Seven % of the
“drug-like” and 21% of the “probe-like” compounds from the MMV malaria box demonstrated equivalent activity against
both asexual and late stage gametocytes.
Conclusions: The assays described were shown to selectively identify compounds with gametocytocidal activity and
have been demonstrated suitable for HTS with the capability of screening in the order of 20,000 compounds per
screening campaign, two to three times per seven-day week.
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Transmission blockingBackground
Malaria is a disease resulting from infection by the intra-
cellular parasite Plasmodium. It remains the most signifi-
cant parasitic disease in the tropics where it causes ~200
million clinical cases and is reported to claim up to 1.2
million lives each year [1]. Substantial efforts are being
made to not only reduce the number of clinical manifesta-
tions and deaths attributed to malaria, but also to the
complete eradication of this disease. The World Health
Organization (WHO) first attempted a global eradication
programme during the period 1955–1969, which was ul-
timately unsuccessful. A recent review of the 1955–1969
campaign points to the lack of suitability of the control
measures taken at that time for all areas involved [2].* Correspondence: v.avery@griffith.edu.au
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article, unless otherwise stated.Some countries were highly successful in achieving eradi-
cation, whereas in others any headway made was lost to
subsequent resurgence of malaria, often in epidemic pro-
portions. International aid for continued malaria control
in endemic malaria regions declined considerably during
the 1970’s and 1980’s, however recent renewed inter-
national efforts into malaria control and research has re-
sulted in promising advances in new control measures.
Artemisinin combination therapy (ACT) has proven
to be the most effective anti-malarial for both treat-
ment and control to date, with the additional benefit
of significantly impacting on the reduction in malaria
transmission [3-5]. In 2007, a renewed effort for glo-
bal eradication of malaria was proposed by the Bill
and Melinda Gates Foundation (BMGF) at the 2007
Malaria Forum in Seattle, Washington [6]. In 2011,
scientists reconvened in Bethesda, to discuss the latesttral Ltd. This is an Open Access article distributed under the terms of the
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ment of Plasmodium and the latest strategies for mal-
arial control. One of the key deliverables identified
from this meeting was the need for phenotypic assays
for the identification of compounds which kill game-
tocytes and ookinetes, and hence may ultimately func-
tion as transmission blocking drugs [7].
Gametocytes arise through a switch from asexual
replication in the human host to sexual forms of the
parasite in a process termed gametocytogenesis. Dur-
ing intra-erythrocytic asexual replication, the stage of the
parasite life cycle responsible for the clinical symptoms of
malaria, limited numbers of the parasite undergo conver-
sion to the sexual form. This sexual differentiation appears
to be triggered and, or controlled by a number of environ-
mental, parasite and host defined mechanisms which are
still not clearly defined. Several of these putative gameto-
cytogenesis inducing factors have been recently reviewed
by Lucantoni & Avery [8].
Gametocytes remain in human host erythrocytes
throughout this conversion and during the prolonged
10–12 day maturation period. Initially, gametocytes are
difficult to differentiate from asexual ring and early
trophozoite stages by standard Giemsa-stained blood
smears. The gametocytes undergo further development,
which is classified into five distinct morphological stages,
termed I to V. The gametocytes continue a morpho-
logical and biochemical development from an early stage
or immature (I-III) to a late stage or mature (IV and V)
gametocyte. Only the fully developed, mature stage V ga-
metocytes, can survive in the mosquito gut environment
where the male and female gametes generated undergo
fertilization with the formation of ookinetes, perpetuat-
ing the transmission cycle from human host through
mosquito vector, and back to the human host.
A number of large-scale high throughput screening
(HTS) campaigns have been performed over the last
five years to identify compounds with activity against
the asexual blood stages of the malaria parasite, Plas-
modium falciparum. Notably, 309,474 compounds by St.
Jude Children’s Research Hospital [9], 2 million by
GlaxoSmithKline Tres Cantos [10] and 1.7 million by
Novartis-GNF (Genomics Institute of the Novartis
Research Foundation) [11] were screened. The not-
for-profit organization, Medicines for Malaria Venture
(MMV) has also been instrumental in obtaining nu-
merous proprietary chemical libraries from both the
pharmaceutical and biotech industries for testing for
anti-malarial activity. The screening of these has been
undertaken predominantly as a joint venture between
MMV and the Eskitis Institute for Drug Discovery, at
Griffith University. The collective outcomes of these
screening campaigns have resulted in the public availabil-
ity of data for numerous sets of compounds with asexualanti-malarial activity. The total number of asexual active
compounds identified through the aforementioned activ-
ities exceeds 25,000. These asexually active compounds
have formed the basis of screening activities to identify
molecules with dual activity against both the asexual and
sexual stages, in a bid to identify molecules with the cap-
ability of not only treating the clinical symptoms, but also
with the added ability to block transmission.
In order to identify dual acting compounds against asex-
ual and gametocyte stages, we have developed a large-
scale, high-yielding, reproducible gametocyte induction
protocol, which provides sufficient gametocytes in the
quantity and quality required to develop HTS assays for
both early (I-III) and late (IV-V) stage gametocytes. Both
assays, utilize high throughput confocal microscopy, with
automated image analysis for detection and quantification
of compound activity against gametocytes. To validate and
demonstrate the capability of these assays to identify com-
pounds with activity against early and late stage gameto-
cytes, 36 compounds used as asexual anti-malarials, in
addition to compounds currently in preclinical develop-
ment were tested, and their IC50 values against both early
and late stage gametocytes determined. The activity of
these compounds against the asexual forms of the parasite
in an image-based assay was also confirmed [12]. The
MMV malaria box was subsequently screened for activity
against both early and late stage gametocytes in HTS for-
mat and active compounds further characterized by deter-
mining their IC50 values. The MMV malaria box [13,14] is
comprised of compounds which were identified as asexual
actives from the Novartis-GNF, St Jude Children’s research
hospital, and the GSK-Tres Cantos (TCAMS) active com-
pound sets, as well as from the screening of commercial
libraries. Two hundred compounds within the MMV mal-
aria box are considered to be drug-like and 200 probe-
like, which may be considered as a representative subset
of the 25,000 asexual active compounds identified over the
last 5 years.
Herein, the first ever comprehensive published data for
anti-malarial compounds with activity against both early
(I-III) and late (IV-V) stage gametocytes is described. The
same gametocyte strain, induction protocol and assay
technology has been utilized to provide this data enabling
a direct comparison of the results obtained. Also included
is the first gametocyte specific data presented for the
MMV malaria box with a complete data set in IC50 format
for activity against both early and late stage gametocytes.
Methods
Asexual culture
Asexual culture was performed using standard culturing
techniques as first described by Trager and Jensen [15].
Specifically, the asexual culture media contained RPMI
with 10 mM Hepes (Invitrogen, Australia), 50 μg/ml
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tion of NF54-pfs16-GFP), 5% pooled human AB male
serum (Sigma, Australia) and 2.5 mg/ml AlbuMAX II®
(Invitrogen, Australia). The parasites were maintained at
0.5-4% parasitaemia (%P) at 5% haematocrit (%H). Hu-
man O + erythrocytes were obtained from the Australian
Red Cross Blood Service (Agreement No: 09-05QLD-06).
Human ethics approval was given by the Griffith
University Human Ethics Committee for the handling
and use of human red blood cells for parasite culture
and experiments performed within this study (ESK/
03/12/HREC and ESK/03/07/HREC). The culture was
adjusted daily to maintain low parasitaemia. All parasite
incubations for both culture maintenance and assay were
performed at 37°C, 5% CO2, 5% O2 and 60% humidity.
Plasmodium falciparum 3D7 asexual assay
The asexual parasite culture and assay was performed as
described previously [12] with only the single modifica-
tion of using 5% serum and 2.5 mg/ml AlbuMAX II® in
combination rather than 5 mg/ml AlbuMAX II® without
serum. In brief, strain 3D7 of P. falciparum was synchro-
nized to early trophozoite (‘ring’) stage parasites using
sorbitol selective lysis as described previously [16]. On
the day of the assay compounds were diluted in water
and 5 μl added to PerkinElmer CellCarrier imaging
plates. Twenty-five μl of asexual assay media was added
to all wells followed by 20 μl of parasite culture at 2% P
and 0.75% H, resulting in a final %H of 0.3%. Plates were
incubated for 72 hours in standard conditions then
stained with 4′,6-diamidino-2-phenylindole (DAPI). The
plates were left for at least 4 hours before imaging on
the Opera QEHS microplate confocal imaging system
(PerkinElmer, Australia). DNA spot analysis was per-
formed and the number of infected red blood cells
(iRBCs) provided as the output. The OPERA output was
defined as the number of classified spots per imaged
area and was calculated as % inhibition based on 2 μM
artemisinin (positive) and 0.4% DMSO (negative) con-
trols. IC50 values were determined using Prizm 4.
Gametocyte induction, culture and isolation
NF54 transgenic parasite expressing GFP linked to lucif-
erase under the control of the early gametocyte specific
pfs16 promoter, Pfs16 [17] were generously provided by
Prof David Fidock, Columbia University, NY and main-
tained in asexual culture as described above. At Day −3
of the induction protocol, mid stage trophozoite para-
sites were isolated on a CS magnetic column (MACS)
and VarioMACS separator (Miltenyi Biotec, Australia).
Fresh non-infected red blood cells (RBCs) were added
to the isolated trophozoites, and the haematocrit reduced
to 1.25%. After overnight shaking, the Day −2 culture was
then put under nutritional stress overnight. Resultingtrophozoite parasites, Day −1, were then adjusted to 3% P
and shaken overnight before removal of spontaneously
generated gametocytes using MACS column gametocyte
depletion on Day 0. Ring stage parasites were then trans-
ferred into gametocyte culture media which was the same
as the asexual media with the addition of 50 mM N-acet-
ylglucosamine (NAG) for removal of asexual parasites.
Post induction, culture and isolation of gametocytes for
the early (I-III) stage assay
Day 0 ring stage parasites, post spontaneous gametocyte
removal, were centrifuged and suspended in asexual
media. The ring stage parasites were split to 4% P and
the %H maintained at 2.5%. The culture was left over-
night to incubate. The following day (Day1 post-
induction) fresh media was added to the mid trophozoite
stage culture by simple aspiration and replacement and
the culture incubated overnight. After overnight incuba-
tion the non-committed asexual parasites were again at
ring stage, however, the committed gametocytes were
now similar to young trophozoite stages and contained
haemozoin. The gametocytes were isolated using the
MAC isolation procedure. Twenty μl of non-infected
compacted RBCs were added per isolated gametocyte
column run (10 ml/run) resulting in a final haematocrit
of between 0.2 and 0.5% H. Determination of % gameto-
cytes was made by both Giemsa-staining and GFP fluor-
escence microscopy. Gametocytes isolated in this
manner were typically stage I/IIa. In preparation for use
in the early stage assay, these I/IIa gametocytes were di-
luted to 10%P in 0.1% H in media containing NAG.
Post induction culture and isolation of gametocytes for
the late (IV-V) stage assay
The Day 0 ring parasites were placed in media contain-
ing 50 mM NAG at 2.5% H, and 50 ml of culture was
placed in 100 mm diameter large Petri dishes. Thirty-five
ml of spent media was replaced daily over 7 successive
days for each culture dish. On Day 8 the gametocytes were
harvested using magnetic columns and RBCs added to the
isolated gametocytes. The final isolated gametocytes and
RBCs were then counted on a haemocytometer, and the
culture adjusted to 10% gametocytes in a total of 0.1% H
in media containing 50 mM NAG.
Early gametocyte (stage I-III) assay protocol
Five μl of diluted compound in 4% DMSO was trans-
ferred in 384-well format into PerkinElmer Cell carrier
Poly-D-Lysine imaging plates using a Minitrack™ liquid
handler (CCS Packard). The day 2 isolated gametocytes
prepared at 10% P and 0.1% H were dispensed in 45 μl
volumes into the imaging plates using a multidrop dis-
pensing instrument (Thermo Scientific, Australia). The
plates were sealed with gas permeable membranes
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for 72 hours in standard incubation conditions of 5%
CO2, 5% O2 and 60% humidity at 37°C. After 72 hours
incubation, 5 μl of 0.07 μg/ml MitoTracker Red CM-
H2XRos (MTR) (Invitrogen, Australia) in phosphate
buffered saline (PBS) was added to each well, and plates
were resealed with membranes and incubated overnight
under standard conditions. The following day, the plates
were brought to room temperature for at least one hour
before being measured on the Opera QEHS Instrument
(PerkinElmer), utilizing a Twister II micro-plate handler
(Perkin Elmer) for automated plate feeding to allow for
“walk away” measurement and image analysis.
Late Gametocyte assay protocol (stage IV-V))
Five μl of diluted compound in 4% DMSO were trans-
ferred in 384-well format into PerkinElmer Cell carrier
PDL imaging plates using a Minitrack™ liquid handler.
The day 8 isolated gametocytes prepared at 10% P and
0.1% H were dispensed in 45 μl volumes into the im-
aging plates using a multidrop dispensing instrument.
The plates were sealed with gas permeable membranes
(4ti-05 15/ST, 4titude Surry, UK,) and incubated for
72 hours in standard incubation conditions. After
72 hours incubation, 5 μl of 0.07 μg/ml MTR in PBS
were added per well, and plates resealed with mem-
branes and incubated overnight under standard condi-
tions. The following day, the plates were brought to room
temperature for at least one hour before being measured
on the Opera QEHS Instrument (PerkinElmer), utilizing a
Twister II microplate handler (Perkin Elmer) for auto-
mated plate feeding to allow for “walk away” measurement
and image analysis.
Opera image acquisition and analysis
Image acquisition and analysis for both the early and late
stage gametocyte assays was undertaken on the Opera
QEHS micro-plate confocal imaging system (PerkinElmer).
Single images were taken for each well at 3 μm from
the bottom of the PerkinElmer CellCarrier plate using a
20X water immersion objective. First, the GFP intensity
was measured and distribution determined with an ex-
posure time of 400 msec (488 nm), then to ascertain the
fluorescence intensity of the viability stain, MTR, mea-
surements were made for 600 msec (532 nm). Autofocus
from the first well was used to correct for the subse-
quent well images. All images, for each well, were ana-
lysed by the Acapella based script and stored directly
into a database as imaged. The script has been optimized
to select objects with a MTR fluorescent signal above an
assay specified cut-off and a GFP object morphology
which was longer than it was wider, specifically the ob-
ject was elongated (Figure 1A). The number of elongated
objects was equivalent to the number of gametocytesper area of the well imaged (Figure 1B). The late stage
gametocytes, after 72 hours incubation and MTR stain-
ing, have a classical stage V morphology as can be seen
from the GFP-MTR image acquired on the Opera QEHS
using 60× magnification (Figure 1C) demonstrating the
continued development path of the gametocytes from
stage IV to stage V within the 384-well micro-titer im-
aging plates.
Demonstration of linearity between parasite number per
well and script detected number of parasites per
imaged area
Day 8 Gametocytes (stage IV) isolated by MACs column
were counted for total number of cells and the number
of gametocyte infected cells. Dilutions were made to the
appropriate number of gametocytes/ml in a final total
haematocrit of 0.1%. It was determined that 75 million
RBCs per ml was equivalent to 1% H, thus allowing for
rapid translation from gametocyte number and RBCs/ml
to %P and %H values [12]. Individual cultures containing
the range of gametocyte numbers per well (1,000-
85,000) were dispensed into 16 wells per cell density and
the plates incubated for 72 hours. After incubation, 5 μl
of MTR (prepared as described above) was added to all
wells and the plates incubated overnight in standard
conditions. The assay plate was then imaged at standard
exposures and the script applied to the images as de-
scribed above. The number of identified gametocytes per
well image (average ± SD) was plotted against the actual
number of gametocytes per well using linear regression
in Graph pad Prizm (Figure 1B).
Compound preparation
Solid anti-malarial compound stock preparations for
IC50 determination
The appropriate volume of 100% DMSO was added to
the vials of solid anti-malarial compounds to give
10 mM final stock concentrates. The compounds were
diluted in 384-well Eppendorf deep well storage block
plates in duplicate point across the plate. The dilutions
made resulted in three concentrations per log dose for
each compound tested. All the dilutions were made in
100% DMSO. For the assays, 1 μl of compound was pre-
diluted into 24 μl of sterile water before addition to the
assay plate to maintain a final DMSO concentration of
0.4%. Samples were tested on the 3D7 asexual, early and
late stage gametocyte assays.
MMV malaria box compound handling
The MMV malaria box compounds were received as
10 mM stocks in 100% DMSO. To maximize the small
volume available, the compounds were further diluted to
a final stock concentration of 2.5 mM in 100% DMSO
and replicate sets of plates made for future use. These
Figure 1 Script analysis and performance of late stage gametocyte assay. A. Top panel no compound treatment. Bottom panel 5 μM
puromycin, 72 hour treated late stage gametocytes. MTR channel mask, GFP channel Mask, analysed Gametocyte Mask and MTR-GFP overlay of
Opera acquired images. B. Linearity graph- gametocyte number per well against script identified viable gametocytes per well. C. Opera acquired
image of gametocytes after 72 hours incubation and MTR staining. A X60 water objective was used to capture detailed images. Classical stage V
gametocytes are observed.
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repeat freeze thawed in order to maintain the integrity
of the compounds. For initial testing, the compounds
were used as either 1/2 or 1/10 dilution in duplicate
point to determine % inhibition at 5 μM and 0.5 μM
compound concentrations. DMSO stock compounds
were diluted 1/25 in water for use in the assays to ensure
a DMSO concentration of less than 0.5%.
Compounds demonstrating >50% inhibition on the
late stage assay at 0.5 μM or >80% at 5 μM were taken
for determination of accurate IC50 values against both
the early and late stage gametocyte assays in duplicate
point. Early stage actives at >50% at 0.5 μM were also
taken for IC50 evaluation against both early and late
stage gametocytes. Compounds demonstrating only low
activity against early stage gametocytes were de-prioritized
at this point and not taken further for retest.Opera data analysis
The Opera script output describes the number of viable
gametocytes identified. The reduction in the number of
gametocytes obtained after compound addition and
72 hours incubation was calculated as a percentage of the
positive and negative controls contained in each assay
plate. The positive control constitutes 16 wells of 5 μM
puromycin and the negative control was 16 wells of 0.4%
DMSO. The individual ‘in-plate’ controls were used to cal-
culate the relative (R) % inhibition of parasite number for
the unknown wells. The equation used is as below.
R % inhibition ¼ 100‐ Unknown‐5 μM puromycinð Þ=
0:4%DMSO‐5 μM puromycinð Þ  100
The relative 100% inhibition control of 5 μM puro-
mycin was used in all calculation as this is relevant for
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specifically on the parasite development and viability
than the use of absolute zero in the form of non-
infected RBC’s.
IC50 calculation
Normalised % inhibition of parasite numbers were plot-
ted against log concentration (conc) of the compound
using a 4 parameter log dose, non-linear regression ana-
lysis, with sigmoidal dose response (variable slope) curve
fit using Prizm 4.0. No constraints were placed on the
top, bottom or Hill slope of the curve fit in the graphing
software. Compounds which did not reach a maximal in-
hibition plateau could not, therefore, have IC50 values
determined by this analysis.
Results
High-throughput confocal imaging and assay linearity
(Late stage IV-V)
Gametocytes were automatically classified and counted
using an Opera QEHS high throughput confocal imager.
Image analysis script parameters were selected to deter-
mine the number of viable late stage gametocytes in the
imaged area. A linear relationship was observed between
the numbers of gametocytes per well determined using a
haemocytometer compared to gametocyte objects auto-
matically calculated (Figure 1B). An r2 value of 0.98 was
obtained and linearity was maintained from 1,000 to
85,000 gametocytes per well.
Current anti-malarial compounds
The IC50 data generated for known anti-malarials against
early and late stage gametocytes, as well as asexual 3D7
parasites, is presented in duplicate point for 21 concen-
trations in Table 1. Compounds were tested at the max-
imum concentration of 40 μM, thus compounds which
did not yield an IC50 value, within the confines of the
analysis parameters, were either expressed as the % in-
hibition at 40 μM or not active (NA) at 40 μM. The se-
lectivity index (SI), a ratio of compound activity on
asexual forms compared to activity in either early or late
gametocytes, an important parameter for determining
dual activity, is also shown in Table 1.
4-Aminoquinolines
Amodiaquine (AQ), naphthoquine (NQ), AQ-13, pipera-
quine (PIPQ), hydroxychloroquine (HQ) and pyronari-
dine (PYRO) all exhibited comparable activity against
both asexual 3D7 parasites and early stage gametocytes
(AQ 255:242, NQ 411:483, AQ-13 183:453, PIPQ1880:
3990, HQ 966: 1340, PYRO 299: 250 nM, 3D7 asexual:
early gametocytes, respectively). However, except for
PYRO, no activity against late stage gametocytes was ob-
served for any of the other compounds tested up toconcentrations of 7 μM. PRYO had an average IC50
value of 4260 ± 240 nM (SD) against late stage gameto-
cytes, and was demonstrated to be 14 times more select-
ive for the asexual parasite than late stage gametocytes.
8-Aminoquinolines
Pamaquine (PAMQ) demonstrated no significant activity
against 3D7 asexual, early or late stage gametocytes.
Primaquine (PQ) exhibited only low levels of activity
(7.12 μM± 1500 (SD)) against the asexual forms in the
3D7 asexual assay, and no significant activity against ei-
ther early or late stage gametocytes. Tafenoquine (TQ)
and NPC-1161B demonstrated equal but low μM activity
against the asexual, early and late stage gametocytes.
(TQ 5.6: 4.8: 4.6 uM, NPC-1161B 3.4:2.2:4.9 μM 3D7
asexual: early gametocytes: late gametocytes respectively).
Endoperoxides
Artemether, dihydroartemisinin (DHA), artesunate, arte-
misinin and artemisone all demonstrated similar activity
between the 3D7 asexual parasite, early gametocytes and
late gametocytes, with IC50 values less than 50 nM.
Antifolates
Of the five antifolates tested, chlorproguanil had simi-
lar activity against the 3D7 asexual parasites and late
stage gametocytes, with low activity (108% inhibition
at 40 μM) against the early gametocytes. Pyrimeth-
amine demonstrated a high level of activity against the
3D7 asexual parasite, with an IC50 value of 21.5, ± 0.07 nM
(SD) but had no activity against either the early or late
stage gametocytes.
Sulphonamides
Of the three compounds of this chemical class tested,
sulphadiazine, sulphamethoxazole and sulphadoxine, none
had activity against asexual or gametocyte stages.
Amino alcohols
The amino alcohols tested included halofantrine (HF),
lumefantrine (LF), mefloquine (MQ) and quinine (Q).
All demonstrated equivalent activity against early and
late stage gametocytes, apart from Q, which was more ac-
tive against the late stage gametocytes than early stage ga-
metocytes. (HF 136:135:32 nM, LF 137:107:2.1 nM, MQ
(Racemic) 158:223:100 nM, Q 217:2110:318 nM asexual:
early gametocytes: late gametocytes, respectively).
Antibiotics
Of the six antibiotics tested, trimethoprim, thiostepton,
clindamycin, mirincamycin (cis and trans isomers) and
tetracycline, only thiostrepton demonstrated comparable
activity against both early and late stage gametocytes
(0.5 – 1 μM), as well as the asexual 3D7 parasite.
Table 1 Activity data for anti-malarial drugs
COMPOUND 3D7a NF54-pfs16-GFPa NF54-pfs16-GFPb (I-III)/ABS (IV-V)/ABS
ABS early (I-III) gam late (IV-V) gam
4-Aminoquinolines
Amodiaquine 255 (65) 242 (110) 87% 0.9
Naphthoquines 411 (82) 483 (330) NA 1.2
AQ-13 183 (0.01) 453 (230) 82% 2.5
Piperaquines 1880 (210) 3990 (2800) 43% 1.6
Hydroxychloroquines 966 (130) 1340 (140) 45% 1.4
Pyronaridine 299 (69) 250 (96) 4260 (240) 0.8 14.2
8-Aminoquinolines
Pamaquine 88% 79% NA
Primaquine 7120 (1500) NA 74%
Tafenoquine 5650 (1600) 4800 (1500) 4620 (1600) 0.8 0.8
NPC-1161B 3360 (860) 2180* 4850 (2700) 0.6 1.4
Endoperoxides
Artemether 25.8 (11) 11 (2.8) 3.13 (0.7) 0.4 0.1
Artenimol (DHA) 2.08 (0.6) 18.3 (17) 2.17 (1.2) 8.8 1.0
Artesunate 6.7 (1.6) 3.8 (0.28) 2.53 (1.10) 0.6 0.4
Artemisinin 41.6 (12) 12.1 (14) 5.47 (2.0) 0.3 0.1
Artemisone 3.72 (0.14) 2.4 (0.85) 1.7 (0.46) 0.6 0.5
Anti folates
Pyrimethamine 21.5 (0.07) NA NA
Chlorproguanil 6250 (520) 108% 4340 (840) 0.7
Proguanil HCl 78% 6540* 84%
Dapsone NA NA NA
Sulphonamides
Sulfadiazine NA NA NA
Sulfamethoxazole NA NA NA
Sulfadoxine NA NA NA
Amino alcohols
Halofantrine 136 (66) 135 (98) 31.9 (11) 1.0 0.2
Lumefantrines 137 (70) 107 (137) 2.07 (0.55) 0.8 0.0
Mefloquine (Racemic) 158 (33) 223 (120) 100 (3.6) 1.4 0.6
Mefloquine (+ RS) 133 (41) 226 (76) 134 (110) 1.7 1.0
Quinine sulfate 217 (0.7) 2110 (280) 318 (180) 9.7 1.5
Antibiotics
Trimethoprim 3740 (120) NA NA
Thiostrepton 913 (210) 959 (570) 556 (58) 1.1 0.6
Clindamycin 325 (64) NA NA
Cis-mirincamycin (HCl) NA NA 64%
Trans-mirincamycin (HCl) 86% NA 66%
Tetracycline 2270 (170) NA NA
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Table 1 Activity data for anti-malarial drugs (Continued)
Other
Fosmidomycin mono sodiums 91% NA NA
Methylene blue trihydrate 21.9 (0.07) 280 (130) 287 (100) 12.8 13.1
Pentamidine 697 (36) 1560 (620) 2850 (540) 2.2 4.1
ABS Asexual blood stage, gam gametocyte, an = 2, bn = 3. IC50 nM (SD), * n = 1 only, NA Not active at 40 μM, % at 40 μM.
sPotential solubility issues with stock
compounds in DMSO.
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Methylene blue and pentamidine were also tested
against all stages. Methylene blue was active against both
early and late stage gametocytes at less than 300 nM,
but was almost 10 fold less active than against the 3D7
asexual parasite. Pentamidine was slightly less active
against early and late stage gametocytes (1.56:2.85 μM
early: late) in comparison to its 3D7 asexual activity
(0.69 μM).
MMV malaria box HTS
Duplicate point screening at 5 μM and 0.5 μM doses
was performed for the MMV malaria box prepared as
described above, on both the early and late stage gam-
etocyte assays. The activity distribution generated forFigure 2 Compound activity distribution against early (I-III) and late (
malaria box compounds against the early (A) and late (B) stage gametocyboth assays (Figures 2A and B) did not produce a nor-
mal distribution; however this was expected due to the
library being primarily comprised of compounds with
demonstrated asexual anti-malarial activity. It is noted
that due to the use of relative % inhibition in relation to
5 μM puromycin some compounds demonstrate a value
greater than 100% inhibition. A number of parameters
can cause this, including compound related effects such
as lysis of all RBCs, specific lysis of iRBCs, or compound
fluorescence quenching of the GFP or MTR signal.
IC50 evaluation was performed on compounds with ac-
tivity greater than 50% for the 0.5 μM dose and, or
greater than 80% at 5 μM, for the late stage gametocyte
assay. IC50 value determination was performed for 97
compounds on fresh stock concentrates. Both early andIV-V) stage gametocytes. Normal distribution of the activity of MMV
tes was not observed as the compound set has an asexual bias.
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evaluation of the 97 early or late stage active compounds
from the MMV malaria box. IC50 value determination was
performed in a single experiment in duplicate point at
16 concentrations per compound tested. The in-plate
controls (comprised of 16 wells of 5 μM puromycin as
the positive control and 16 wells of 0.4% DMSO as the
negative control) for 25 × 384-well plates tested to obtain
accurate IC50 values, for early and late stage gametocyte,
are presented in Figures 3A and B. The average signal:
background values were 13.2 ± 5.5 (SD) and 6.9 ± 0.76
(SD) for early and late, respectively, with Z’ values of
0.68 ± 0.1(SD) and 0.53 ± 0.08 (SD), respectively. The
performance of the assays was highly stable from the
first to last plates with good reproducibility within a sin-
gle plate. Unfortunately, IC50 values for 25 of these com-
pounds could not be determined for either early and/or
late stage assays due to low activity or an inability to
generate suitable curves. Many of the compounds were
also shown to be insoluble in water and thus the neces-
sary dilution of DMSO for performing the assay was
limiting.
Seventy-two compounds had IC50 values ≤1600 nM
for either early or late stage gametocytes and were in
this case classified as actives as an IC50 was obtainable
from the Prizm calculation. Compound activities were
then assessed according to their “drug-like” (20) or


























































Figure 3 In plate control data for early (I-III) and late (IV-V) stage gam
the MMV malaria box against A. early (I-III) and B. late (IV-V) stage gametoc
0.4% DMSO) and purple triangles indicate 100% inhibition (5 μM puromyciThe data for the IC50 values (nM) for both the early and
late gametocyte assays for the “drug-like” compounds
were plotted against the corresponding 3D7 data pro-
vided by MMV and originally generated within this
laboratory (Figure 4A). Where an IC50 value was not
obtainable a maximum IC50 value of 2,000 nM was as-
signed to the sample for graphing purposes to indicate
not active (NA) at 5,000 nM or activity greater than
2,000 nM.
Only 20 of the 200 compounds classified as ‘drug-like’
(10%) had activity against either early or late stage game-
tocytes. Of the 20 ‘drug-like’ active compounds, 7 (35%)
were active against both early and late stage gameto-
cytes, 9 (45%) were active against late stage gametocytes
only and 4 (20%) were classified as active against early
gametocytes only. When considering the degree of activ-
ity against the asexual parasite for the 200 ‘drug-like’
compounds in comparison to the late stage gametocyte
activity, only 14 (7%) had activity with less than fivefold
difference in IC50 values, indicating equipotent activities
between asexual and late gametocyte stages. One com-
pound in particular, MMV666693, although very active
against the 3D7 asexual parasite (23.8 nM) was 18.4
times less active against the late stage gametocyte and
not active against the early stage gametocytes at all. As
late stage gametocyte activity equal to or better than
asexual activity is widely considered to be essential for




etocyte assays. In-plate control data obtained during screening of
ytes is shown. Black squares represent no inhibition (vehicle control:
n).
Figure 4 Early and late stage gametocytocidal activity of MMV Malaria Box “drug-like” compounds aligned with 3D7 asexual activity.
A. Activity of compounds classified as "drug-like". B. MMV019918 IC50 evaluation. C. MMV007907 IC50 evaluation. Orange triangles are indicative of
the early (I-III) stage gametocyte activity whereas the blue squares represent the late (IV-V) stage gametocyte activity.
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within the MMV malaria box would be selected for pro-
gression on this basis. Of particular note are MMV019918
and MMV07907 which have IC50 values <1,000 nM
against all three stages tested (Figure 4B and C).
Of the 200 ‘probe-like’ compounds tested, 52 (26%)
gave an IC50 value for either early, late or both gameto-
cyte stages ≤1600 nM and were classified as actives
(Figure 5). Of these 52 ‘probe-like’ compounds 16
(31%) demonstrated activity against both early and
late stage gametocytes, 32 (61%) showed late stage ac-
tivity only whilst only 5 (9.6%) of the 52 probes ex-
hibited activity for early stage gametocytes only. Of
the 200 “probe-like” compounds, 41 (21%) with late
stage activity had less than a five-fold reduced activity
against late stage gametocytes in comparison to the
asexual activity. This is significantly higher than that
for “drug- like” compounds (7%). It would, therefore, ap-
pear that the ‘probe-like’ compounds within the collection
have a higher hit-rate on these gametocyte assays than the
‘drug-like’ compounds (26% “probe-like” late stage gam-
etocyte active in comparison to 10% “drug-like” late stage
gametocyte active), Additionally, in general the more
“probe-like” compounds have comparable asexual and late
stage gametocyte activity than the “drug-like” compounds.The HTS screening data for the MMV malaria box at
5 μM and the IC50 values obtained (nM) are incorporated
in Additional file 1.
Discussion
To perform the gametocyte screening assays it was es-
sential to not only have healthy gametocytes in sufficient
quantities, but also to be capable of producing highly re-
producible quantities according to the required HTS
schedule. With the specifically optimized synchronous
gametocyte induction and isolation protocol described
above, quantities of gametocytes sufficient for 50 × 384-
well imaging plates (almost 20,000 data points) were able
to be produced two to three times per week. The assays
described here were able to detect compounds which
prevented the development of gametocytes from stage I
to stage III or kill stage IV/V gametocytes.
The linearity calibration conducted during the valid-
ation of this assay showed a linear relationship between
actual number of gametocytes added per well, as defined
by the use of a haemocytometer, and those gametocytes
identified per imaged area within a well using the auto-
mated image analysis algorithm. Using 33,000 gameto-
cytes per well (384-well plate) in a HTS assay format, an
average signal to background (S:B) ratio of 13.2 ± 5.5,
Figure 5 Early and late stage gametocytocidal activity of MMV Malaria Box “probe-like” compounds aligned with 3D7 asexual activity.
The activities of compounds from the MMV malaria box for the early (I-III) (orange) and late (IV-V) (blue) gametocyte stages are aligned with the
activities determined for 3D7 asexual parasites (grey). All three assays were performed using image based assays and analysis.
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the early and late stage gametocyte assays, respectively
were obtained. This data was generated for a screening
run of 25 assay plates in 384-well formats, which trans-
lates to 9,600 data points.
Several laboratories have developed assays to measure
compound activity against late stage gametocytes. Unfor-
tunately, it is difficult to directly compare these assays
and associated compound activities with one another as
the same compounds have not been screened in all cases.
In some instances IC50 values have been determined,
whereas in others only the % inhibitions at a specific single
concentration have been indicated. In addition, the vari-
ous assays employ different gametocyte induction proto-
cols and parasite strains, isolation protocols, gametocyte
densities per well, the presence or absence of RBCs, com-
pound incubation times and media components, as well
as methods for detection, which may all have some effect
on the results obtained. It is therefore only possible to
perform a limited comparison between the compound
activities determined by the different assays. Thus, the
interpretation of the observed differences and similar-
ities, and resultant implications must be treated with
caution. For example two independent laboratories
[18,19] have developed late stage gametocyte assays,
both using ATP bioluminescence as the measure of
parasite viability, and screened some, if not all of the
36 current anti-malarials described here. Although the
same thirteen compounds were tested by both groups,
one performed IC50 values directly whilst the other
screened at 10 μM first to select actives. Three com-
pounds have IC50 data presented in both publications,
which are methylene blue 490 nM and 12 nM, artesu-
nate 10.8 μM and 2.3 μM and pyronaridine 3.2 μM
and 0.28 μM. Although the detection method was
based on the same technology, incubation times and
gametocyte numbers per well were different and may pro-
vide the explanation for the variations observed. An assay
based on the gametocyte specific NF54-mal8p 1.16- lucif-
erase transgenic parasite [17] has also been use to test
activity of a selection of anti-malarial drugs. Activity
was expressed in % activity ranges for fixed compound
doses related to asexual determined IC50 values. DHA was
demonstrated to result in 50-75% inhibition of late stage
gametocytes at a fixed dose of 120 nM in comparison
to less than 50% inhibition for 10 μM or 3.6 μM ob-
tained by ATP bioluminescence [18,19]. Methylene
blue exhibited >75% inhibition at 150 nM, which is
comparable to the data reported for the ATP Bio-
luminescence assay [18]. An assay based on lactate
dehydrogenase (pLDH) detection, where parasite LDH
has higher activity than that of RBCs, was recently re-
ported [20]. This assay is undertaken in two formats,
one for 72 hours with the drug in contact with thegametocytes and one where the drug is removed after
72 hours exposure and the plates incubated for a fur-
ther 72 hours. DHA and methylene blue were both
recorded as having activity >400 nM at 72 hours, and
17 and 29 nM, respectively after a further 72 hours
of incubation in the absence of drug. This group also
tested the non-specific compound, epoxomicin, for
which an extended incubation format resulted in an
IC50 value of 3.9 nM. Epoxomicin was also tested in
an ATP bioluminescence assay and gave an IC50 value
of 0.42 nM [18]. Yet another late stage gametocyte
assay using the oxido-reduction indicator Alamar blue
has been published which also tested epoxomicin [21]
generating an IC50 value of 1.4 nM. This compound
has been tested in the late stage (IV-V) gametocyte
imaging assay described here resulting in an average IC50
value of 0.66 ± 0.26 nM over 19 experiments. Notably, this
compound, whilst non-specific for the malaria parasite
when tested in four different assays, has the most consist-
ent result compared with any other compound tested.
Specific anti-malarial compounds have somewhat of a
more variable result within the assays reviewed. When
comparing the data obtained from the imaging assays de-
scribed here for known anti-malarial compounds some
significant differences and similarities with those pre-
sented within the published literature are seen. In general
major differences have been observed between results ob-
tained for the endoperoxides.
Although previously it has been widely accepted, or at
least predicted, that these compounds are not, or will
not be active against late stage gametocytes, in fact all
members of this class of compounds result in the death
of late stage gametocytes in the assays described here.
Artesunate has an average IC50 value of 3 nM against
late stage gametocytes as determined using the imaging
assay. Figure 6 shows the IC50 plot for artesunate and
the number of viable elongated gametocytes identified
decreasing with increasing compound concentration.
The parasites within the wells can clearly be seen to
have lost MTR staining with complete disruption of
gametocyte structure at 50 nM dosing. This is compar-
able to the effect observed for the GFP-MTR overlay for
the 5 μM puromycin control in Figure 1A.
From this very limited literature review of in vitro ac-
tivity against late stage gametocytes in high throughput
micro-titre well formats, endoperoxides (namely, DHA
or artesunate) are demonstrated to be nM active against
late stage gametocytes in one gametocyte specific lucifer-
ase reporter assay [17], a pLDH assay [20] plus the late
stage gametocyte imaging assay described here. Two as-
says, both using ATP bioluminescence [18,19], demon-
strate low μM activity of endoperoxides against late
stage gametocytes. From a literature search, other publi-
cations which tested the endoperoxides directly on late
Figure 6 Images with masked viable elongated gametocytes treated with five concentrations of artesunate. Representative images of
the impact of increasing concentrations of artesunate on late stage (IV-V) gametocytes. Graphic illustration of the activity profile of artesunate
against the late stage (IV-V) gametocytes activity.
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not identified. However, other independent laboratories
have used endoperoxides as controls for anti-gametocyte
activity testing using more traditional Giemsa smears
and microscopy, reporting an IC50 value of 108 nM for
artesunate [22].
The data generated for the endoperoxides within these
image based assays clearly show equipotent activity
against asexual, early and late stage gametocytes which
has previously never been demonstrated. This is a vital
piece of information for interpreting field based studies
on transmission rates and transmission blockage. Al-
though numerous reports of reduced transmission rates
with ACT are presented, the rational for the effect has
been predominantly based on the belief that the action
is due to the extremely fast clearance of asexual para-
sites, and action specifically against young sequestered
gametocytes. However, the data presented here would
indicate that the action could also be against more ma-
ture forms of gametocytes released into the circulation.
Some advantages of the image based gametocyte as-
says are, the same gametocytes, reagents and technology
are used for both early and late stage assays and hence
the data can be compared directly. The confocal fluores-
cent microscopy output is a direct measurement of com-
pound effect on individual gametocytes and not the
contents of a well in total. The Pfs16-GFP and MTR sig-
nal are both specific to the gametocyte as erythrocytes
do not express Pfs16 or have mitochondria to convert
the MTR viability marker. Hence the host RBC has no
direct impact on the assay output.With this comprehensive evaluation and validation of
compound activity against both early and late stage ga-
metocytes for current anti-malarial drugs, a benchmark
for comparison of unknown compounds was established.
The MMV malaria box, provided a starting point for the
search for compounds with activity against the asexual
parasite and also against both early and late stage game-
tocytes. Compounds with activity against both early and
late stage gametocytes were equally distributed through
the “drug-like” (35%) and “probe-like” (31%) compounds
within the MMV malaria box. However, the “probe-like”
compounds resulted in a 16% higher hit rate for late
stage gametocytes than the “drug-like” compounds,
whereas the reverse was true for the early stage gameto-
cytes, with twice the number of the “drug-like” com-
pounds being actives. The “probe-like” compounds also
have three times the number of compounds demonstrat-
ing asexual and late stage gametocyte activity at less
than a five-fold difference and hence, considered to be
equipotent against both the asexual blood stage parasites
and late stage gametocytes. Of particular note are
MMV007907 and MMV019918 which have IC50 values
< 1000 nM against all three stages tested (Figure 4B and
C). These compounds fall into the “drug-like” classifica-
tion given to the MMV malaria box compounds. Having
biological activity against the asexual blood stages, early
and late stage gametocytes, in addition to their “drug-
like” chemical characteristics have ear-marked these
compounds for further investigation.
It could be interpreted from the data that compounds
with the classified “drug like” properties are less likely to
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asexual blood stage parasites. However, this is a small
compound subset and the exact breakdown of the
“drug-like” and “probe-like” actives has not been consid-
ered in this instance. Based on this data it could be ex-
trapolated that only 14% of the compounds identified as
asexually active, irrespective of “drug-like” status, would
potentially result in compounds with equipotent activity
against asexual blood stage parasites and late stage ga-
metocytes. This is not taking into consideration the ac-
tivity against early stage gametocytes, which makes the
number of total compounds with equipotent activity
less.
Hence, 14% of 25,000 asexual actives could potentially
yield 3,500 chemical starting points. It must be noted
that activity against early or late stage gametocytes does
not guarantee that a compound will have transmission-
blocking ability in the field or indeed within in vivo
models. The outcome of these HTS assays is the identifi-
cation of compounds with activity against gametocytes.
With the HTS capacity of the assays described, hundreds
of thousands of compounds can be screened for anti-
gametocyte activity, enriching the potential compound
sets for testing in lower throughput in vitro and in vivo
transmission blocking assays. Essentially, having more
chemical starting points to screen in transmission block-
ing in vitro and in vivo assays should ultimately increase
the odds of finding a compound capable of transmission
blockage.
A new lead compound, ELQ-300 (Quinolone-3-diary-
lether) has demonstrated significant in vivo transmission
blocking potential in mouse models of transmission [23].
This compound was tested using this late stage gameto-
cyte imaging assay and has an IC50 value of 71.9 nM
[23] indicating the late stage gametocyte assay as having
the ability to identify compounds with transmission
blocking potential. The testing of asexual active com-
pounds against gametocytes is an obvious starting point
to search for compounds active against gametocytes
(25,000 in total), however the alternative approach is to
screen whole libraries for compounds active against late
stage gametocytes. This late stage gametocyte assay is
fully capable of screening compounds in true HTS for-
mat, namely the screening of hundreds of thousands of
compounds.
Conclusion
The development of two image based assays for deter-
mining activity against early and late stage gametocytes
has enabled a comprehensive examination of gametocyte
stage specific activity for current anti-malarial drugs and
identification of potential new anti-malarial chemical
starting points. The same parasite and gametocyte in-
duction protocol, as well as the same technology wasused for both early and late assays allowing for a direct
comparison of compound activity. To enable direct com-
parison with the asexual activities the gametocyte num-
bers used in the assays were adjusted to be similar to the
asexual image based assay. Ultimately, a panel of assays,
directly comparing asexual, early and late stage gametocyte
activity in comparative conditions has been established.
The data for in-plate controls, signal to background and Z’
demonstrate the stability of the gametocyte assays over 25
individual 384-well assay plates screened as a single screen-
ing campaign. This is equivalent to 9,600 data points per
assay. Not only has activity for a range of current anti-
malarials and activity for unknowns been identified, the
suitability of these gametocyte imaging assays to be per-
formed in true HTS mode has been demonstrated. It is be-
lieved this is the first HTS screening data presented for
comparison of activity against early stage (I-III) and, of par-
ticular importance, late stage (IV-V) gametocytes.
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